Abstract:312 Background: Currently, there are no standard perioperative regimens for human epidermal growth factor receptor 2 positive (HER2+) gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. Furthermore, despite advances in neoadjuvant or perioperative chemotherapy, the efficacy of treatment for locally resectable advanced GC or GEJ cancer remains unsatisfactory. To address this need, we evaluated the effectiveness of adding atezolizumab (programmed death ligand-1 inhibitor) to treatment with trastuzumab (a HER2 antibody) + capecitabine and oxaliplatin (XELOX) compared with trastuzumab + XELOX in patients eligible for surgery with HER2+ locally advanced GC or adenocarcinoma of the GEJ. Methods: Patients aged 18–75 years were randomized 1:1 to atezolizumab + trastuzumab + XELOX (Arm A) or trastuzumab + XELOX (Arm B) and received the regimen for three neoadjuvant cycles (3 weeks per cycle) and five adjuvant cycles. Treatment administration was atezolizumab 1200 mg, trastuzumab 6 mg/kg, oxaliplatin 130 mg/m 2 intravenously on Day 1, and capecitabine 1000 mg/m 2 orally twice daily on Days 1–14 of each 3-week cycle. The primary endpoint was the pathological complete regression (pCR) rate. Secondary endpoints were the objective response rate (ORR) during neoadjuvant systemic therapy (NAST) and the R0 resection rate. Time-to-event endpoints are not reported because of immaturity. Efficacy endpoints were analyzed in the intention-to-treat population. The clinical cutoff date for the primary analysis was 12 March 2023. Results: Forty-two Asian patients who provided informed consent were screened and randomized to Arm A (n = 21) or Arm B (n = 21); all patients completed NAST. Most patients were male (92.9%), and the median (range) age was 61 (33–72) years in Arm A and 65 (49–72) years in Arm B. The pCR rate was 38.1% (8/21) in Arm A and 14.3% (3/21) in Arm B (treatment difference: 23.8% [90% confidence interval (CI), 1.3%–44.7%]). The pCR rate was significantly better in Arm A than in Arm B (P = 0.079 <0.1; lower limit of the 90% CI >0). Subgroup analysis showed that age <65 years, male sex, and intestinal Lauren classification were associated with a better pCR rate for the atezolizumab inclusive treatment arm (Arm A); however, these results require further confirmation in future studies. No significant difference was detected between the two arms in ORR during NAST or the R0 resection rate. Conclusions: The addition of atezolizumab to trastuzumab + XELOX therapy was effective in patients with HER2+ locally advanced resectable GC or adenocarcinoma of the GEJ. Clinical trial information: NCT04661150 .

Trastuzumab Plus Docetaxel and Capecitabine for First-Line Treatment of Her2-positive Advanced Gastric Cancer: A Phase II, Multi-Center, Open-Label, Singlearm Study.

Trastuzumab Plus Docetaxel And Capecitabine As A First-Line Treatment For Her2-Positive Advanced Gastric Or Gastroesophageal Junction Cancer: A Phase Ii, Multicenter, Open-Label, Single-Arm Study

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

A Multicenter, Phase II Study of Trastuzumab Plus Capecitabine and Oxaliplatin (XELOX) As First-Line Chemotherapy for HER2-positive Advanced Gastric Cancer: Update Results of Efficacy and Toxicity.

[Trastuzumab Combined with Chemotherapy in Patients with HER2-positive Chemo-Refractory Advanced Gastric or Gastro-Esophageal Junction Adenocarcinoma].

Surgical Resection of Advanced Gastric Cancer Following Trastuzumab/Oxaliplatin/Capecitabine Combination Therapy

Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase Ⅲ, multi-center,randomized controlled trial, Chinese subreport

Trastuzumab in Combination with Chemotherapy Versus Chemotherapy Alone for Treatment of HER2-positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (toga): a Phase 3, Open-Label, Randomised Controlled Trial

Late Stage Gastric Cancer Patients With Extra Gained Her2 Positivity By Dual Block Assessment May Not Show Compromised Efficacy To Trastuzumab Treatment

Atezolizumab and Trastuzumab Plus Chemotherapy in Patients with HER2+ Locally Advanced Resectable Gastric Cancer or Adenocarcinoma of the Gastroesophageal Junction: A Multicenter, Randomized, Open-Label Phase II Study.

Treatment Patterns, Effectiveness, and Safety of Trastuzumab in Chinese Patients with Metastatic Gastric Cancer: Interim Analysis of the EVIDENCE Registry Study.

Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells in Vitro and in Vivo

Efficacy Results from the Toga Trial: A Phase Iii Study of Trastuzumab Added to Standard Chemotherapy (ct) in First-Line Human Epidermal Growth Factor Receptor 2 (Her2)-Positive Advanced Gastric Cancer (Gc)

Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer

Immune checkpoint inhibitors combined with HER-2 targeted therapy in HER-2 positive gastroesophageal cancer

The Multicenter, Phase Ii Prospective Study of Paclitaxel Plus Capecitabine As First-Line Chemotherapy in Advanced Gastric Carcinoma

Treatment Patterns and Outcomes in Chinese Gastric Cancer by HER2 Status: A Non-Interventional Registry Study (EVIDENCE).

Efficacy Of Trastuzumab Beyond Progression In Her2 Positive Advanced Gastric Cancer: A Multicenter Prospective Observational Cohort Study

Anti-PD-1 Antibody HX008 Combined with Oxaliplatin Plus Capecitabine for Advanced Gastric or Esophagogastric Junction Cancer: a Multicenter, Single-Arm, Open-Label, Phase Ib Trial

[Capecitabine Combined with Cisplatin As First-Line Therapy in Chinese Patients with Advanced Gastric Carcinoma-a Phase II Clinical Study].

Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2 (Her2)-Positive Early-Stage Breast Cancer: A Real-World Retrospective Study in Chinese Patients.